Toronto, Canada, March 24th 2015: Tissue Regeneration Therapeutics Inc. (TRT) today
announced it has received notice from the Korean Intellectual Property Office that its
patent: IMMUNE PRIVILEDGED AND MODULATORY PROGENITOR CELLS, has been
granted as Korean Patent 10-1507174.

This latest addition to the TRT patent portfolio further validates and extends the TRT stem
cell technology platform. This patent has already been allowed in the United States,
Australia, Canada and Japan, and is pending in all other major territories worldwide.

TRT is a progressive biotechnology company with a focus on the commercial development
of our patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform technology
and its TXP family of cell therapy products. TRT has discovered the world’s richest source
of mesenchymal stromal/stem cells (MSCs) with potent regenerative, angiogenic, anti-
inflammatory, and immuno-regulatory properties. Unique advantages of the TRT HUCPVC
platform technology are founded on the highly enriched source of these important cells
compared to other tissue sources. Specifically, HUCPVCs represent high cell yields at
harvest from tissue normally discarded at birth; high frequencies of mesenchymal stromal
cells within the harvested population, their increased biological potential compared to cells
derived from adult tissues and their inexhaustible supply.

About TRT
TRT is a Canadian Controlled Private Corporation (CCPC) with a focus on the commercial
development of their patented Human Umbilical Cord PeriVascular Cell (HUCPVC)
platform technology and its TXP cell therapy products. TRT is the only company in the
world to have issued and allowed patents in the USA, Europe and Australasia, for extraction
of these unique cells from umbilical cord tissue. TRT provides license opportunities to
collaborating partner companies in the regenerative medicine, defense, and family banking
sectors. Additional information is available at https://www.verypowerfulbiology.com